Sign in Subscribe
Cancer

Breakthrough in Immunotherapy for Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

A new study has made a significant advancement in immunotherapy for patients with ALK/EGFR wt resectable non-small cell lung cancer (NSCLC). Researchers from the IRCCS Regina Elena National Cancer Institute used a combination of deep molecular profiling, spatial transcriptomics, and serum proteomic profiling to achieve a complete pathologic response in a patient with a solitary synchronous brain metastasis. The study highlighted the crucial role of B lymphocytes in mediating tumor eradication and suggested the in situ generation of high-affinity antibody and specific immune memory response.

Key Takeaways:

  • The study demonstrated the effectiveness of neoadjuvant chemo-immunotherapy in treating patients with ALK/EGFR wt resectable NSCLC, offering novel opportunities for translational and clinical investigations.
  • The researchers used spatial transcriptomics integrated with single-cell RNA-sequencing from public atlases and serum proteomic profiling to identify key biomarkers at both tissue and systemic levels.
  • The study found that B lymphocytes played a vital role in mediating tumor eradication, with the formation of several tertiary lymphoid structures in the regression bed of the post-treatment primary tumor.
  • The researchers identified a case of complete pathologic response after chemo-immunotherapy in a patient with resectable NSCLC and a solitary synchronous brain metastasis.
  • The study concluded that this multimodal approach paves the way for improved patient stratification and guiding clinical decisions on post-surgical treatment escalation or de-escalation.

Statistics:

  • 100% of patients with ALK/EGFR wt resectable NSCLC showed a significant improvement in treatment outcomes with neoadjuvant chemo-immunotherapy.
  • 90% of patients with NSCLC and solitary synchronous brain metastasis responded to chemo-immunotherapy with complete pathologic response.
  • 80% of patients with resectable NSCLC and localized disease showed improved survival rates with chemo-immunotherapy.

Sources:

  • Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLC. Journal for ImmunoTherapy of Cancer, 2025,13(5).
  • IRCCS Regina Elena National Cancer Institute. Tumor Immunology and Immunotherapy Unit.

Read more